Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Frequently asked questions
What sector does Amplia Therapeutics Limited (INNMF) operate in?
Amplia Therapeutics Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Amplia Therapeutics Limited (INNMF) current stock price?
As of the latest data, Amplia Therapeutics Limited stock price is $0.06, with a previous close of $0.06.
What is Amplia Therapeutics Limited (INNMF) current market capitalization?
Amplia Therapeutics Limited market cap is approximately 28.23 million.
What is Amplia Therapeutics Limited (INNMF) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
Does Amplia Therapeutics Limited (INNMF) pay dividends?
No. Amplia Therapeutics Limited does not pay a dividend.
What is Amplia Therapeutics Limited (INNMF) beta (volatility) score?
Amplia Therapeutics Limited has a beta of -0.326, indicating lower volatility than the overall market.